Holiday Notification: Cayman Chemical will be closed Monday, May 28, 2012, in observance of the Memorial Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, May 29, 2012. Thank you for your patience and understanding.
EpETrE metabolizes arachidonic acid such as 11(12-EpETrE and 14(15)-EpETrE have been identified as endothelium derived hyperpolarizing factors with vasodilator activity.1 Soluble epoxide hydrolase (sEH) catalyzes the conversion of EpETrEs to the corresponding DiHETrEs thereby diminishing their activity.2 Inhibitors of sEH may therefore have clinical utility for treating hypertension and systemic inflammation.3,4 PHOME is a fluorogenic substrate for human sEH which displays good aqueous stability and solubility making it ideal for high throughput screening (HTS) programs. Hydrolysis of the substrate yields a highly fluorescent product that can be monitored at excitation and emission wavelengths of 330 and 465 nm, respectively. This fluorescent assay has a sensitivity that is 100 times greater than previously used spectrophotometric assays.5 NOTE: This substrate should only be used with the pure EH. If this substrate is used with crude enzyme preparations it is critical that all esterase activity is removed or inhibited, such as with organophosphate or a trifluoroketone inhibitor, and that glutathione is depleted and/or glutathione S-transferase is inhibited.
1
Fleming, I. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol Res49525-533(2004).
2
Morisseau, C., Goodrow, M.H., Newman, J.W., et al. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol631599-1608(2002).
3
Imig, J.D., Zhao, X., Zaharis, C.Z., et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension46(2)975-981(2005).
4
Schmelzer, K.R., Kubala, L., Newman, J.W., et al. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA102(28)9772-9777(2005).
5
Wolf, N.M., Morisseau, C., Jones, P.D., et al. Development of a high-throughput screen for soluble epoxide hydrolase inhibition. Anal Biochem35571-80(2006).
Room temperature
in continental US; may vary elsewhere
SMILES
Copy SMILES to clipboard
COc1ccc2cc(ccc2c1)C(CN)OC(=O)CC1OC1c1ccccc1
Background Reading
Fleming, I. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol Res49525-533(2004).
Brownstein, M.J., Russell, J.T., and Gainer, H. Synthesis, transport, and release of posterior pituitary hormones. Science207373-378(1980).
Morisseau, C., Goodrow, M.H., Newman, J.W., et al. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol631599-1608(2002).
Imig, J.D., Zhao, X., Zaharis, C.Z., et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension46(2)975-981(2005).
Schmelzer, K.R., Kubala, L., Newman, J.W., et al. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA102(28)9772-9777(2005).